Venous Thromboembolism

Background

Venous thromboembolism (VTE) is a common and potentially fatal condition characterized by the formation of blood clots within the veins. It encompasses two primary manifestations: deep vein thrombosis (DVT), which typically involves clots in the deep veins of the legs, and pulmonary embolism (PE), a life-threatening complication where a DVT dislodges and travels to the lungs, blocking blood flow.^[1] VTE is a significant health concern, with an estimated annual incidence of 108 per 100,000 person-years among USA whites, and rates increasing exponentially with age for both men and women.^[1] Approximately 2 million adults in the United States develop DVT each year, leading to an estimated 600,000 PE hospitalizations and 60,000 deaths.^[2]VTE is considered the third most common life-threatening cardiovascular condition, following coronary heart disease and stroke.^[3] Studies indicate a high prevalence of clinical VTE in the USA, with ongoing trends and projections.^[4]and real-world population studies further detail its incidence and mortality.^[5]

Biological Basis

The formation of VTE involves a complex interplay of genetic and environmental factors affecting blood coagulation and fibrinolysis pathways. Family and twin studies consistently demonstrate that VTE is highly heritable, with heritability estimates ranging from 35% to 62%.^[6] This suggests a multigenic basis for the condition, influenced by various genetic predispositions and environmental exposures.^[1] Several genetic variants have been identified that affect the regulation of hemostasis, the process by which blood clots are formed and dissolved.^[1] These include mutations that impair the anticoagulant pathway, such as Factor V Leiden (F5).^[7] or up-regulate the procoagulant pathway, such as the prothrombin G20210A variant in the prothrombin gene.^[1] Other genetic factors can downregulate fibrinolysis (clot breakdown) or up-regulate innate immunity, contributing to VTE risk.^[1] Genetic variations associated with plasma von Willebrand factor levels also play a role in the risk of incident venous thrombosis.^[8] Despite a growing number of identified genetic variants, known genetic polymorphisms currently explain only about 5% of the total genetic variance of VTE, indicating a substantial “missing heritability” that may involve gene-gene interactions or other complex genetic architectures.^[6] The concept of Virchow’s triad (stasis, endothelial injury, and hypercoagulability) provides a foundational understanding of VTE pathophysiology.^[9]

Clinical and Social Importance

VTE is a major public health concern due to its high mortality and significant morbidity.^[10] For a notable proportion of PE patients, the initial clinical presentation can be sudden death.^[1] and VTE is reported to cause tens of thousands of deaths annually.^[11]Beyond acute events, VTE can lead to long-term complications such as post-thrombotic syndrome, which can cause chronic pain, swelling, and skin changes in the affected limb, significantly impacting quality of life.^[12] The economic burden of VTE is substantial, involving considerable healthcare costs and lost productivity.^[13] Understanding the genetic underpinnings of VTE is crucial for identifying individuals at higher risk, developing personalized prevention strategies, and improving clinical outcomes.

Methodological and Statistical Considerations

Studies on venous thromboembolism (VTE) genetics often face methodological and statistical limitations that impact the robustness and generalizability of their findings. A significant challenge lies in achieving sufficient statistical power, particularly for detecting genetic variants with modest effect sizes. Early genome-wide association studies (GWAS) often had sample sizes too small to identify such variants, with estimates suggesting that cohorts of at least 20,000 patients are required to detect genome-wide significant odds ratios as low as 1.10.^[14] This limitation means that many true associations, especially those with subtle influences on VTE risk, may remain undiscovered or require extensive meta-analyses for validation.

Further constraints arise from study design aspects, including potential cohort biases and inconsistencies in phenotype . For instance, some studies have utilized control groups that were not fully matched to VTE cases for demographic factors such as gender and sex, which could introduce confounding, although the identification of known VTE-associated loci suggests this impact might be modest.^[14] Additionally, when combining data from multiple cohorts, variations in how VTE phenotypes are measured or defined across studies can introduce between-group variability, potentially reducing statistical power and complicating the interpretation of pooled results.^[8] These factors necessitate careful consideration when interpreting reported effect sizes and assessing the overall reliability of genetic associations.

Population Diversity and Phenotype Definition

The generalizability of genetic findings for VTE is often constrained by the limited diversity of study populations and varied approaches to phenotype definition. Many large-scale genetic analyses, particularly early GWAS, have predominantly focused on individuals of European ancestry.^[8] This focus can limit the applicability of identified risk variants to other populations, as evidenced by research specifically identifying unique VTE-susceptibility variants in African-Americans, underscoring the importance of diverse cohorts for comprehensive understanding.^[1] Consequently, findings from predominantly European cohorts may not fully capture the genetic architecture of VTE in other ancestral groups, potentially leading to disparities in risk prediction and therapeutic strategies.

Inconsistencies and limitations in VTE phenotype ascertainment also pose challenges to genetic discovery and interpretation. Some studies have relied on self-reported VTE events, which may introduce misclassification bias compared to objectively confirmed diagnoses.^[15]Furthermore, certain studies have explicitly excluded individuals with well-established severe genetic predispositions, such as factor V Leiden or prothrombin 20210A mutations, or deficiencies in antithrombin, protein C, or protein S.^[14] While this exclusion might aim to focus on novel common variants, it means the findings may not fully represent the genetic landscape of VTE in the broader patient population, where these known high-penetrance factors play a significant role.

Complex Etiology and Unexplained Variation

Despite significant advancements in identifying genetic loci associated with VTE, a substantial portion of its heritability remains unexplained, highlighting the complex and multifactorial nature of the disease. The narrow-sense heritability of VTE is estimated to be approximately 30%.^[16] yet common genetic variants identified to date account for only a fraction of this inherited risk, a phenomenon often referred to as “missing heritability”.^[17] This suggests that much of the genetic predisposition to VTE may be attributed to rarer variants, complex gene-gene interactions (epistasis), or structural variations not fully captured by current genome-wide association approaches.

Further compounding the challenge is the intricate interplay between genetic and environmental factors in VTE etiology. VTE is acknowledged as a complex disease influenced by both genetic and environmental determinants.^[16]with studies implicating environmental factors such as obesity as a causal risk factor.^[16] Current genetic studies often do not fully elucidate these complex gene-environment interactions, meaning that a complete understanding of VTE risk requires integrating environmental exposures with genomic data. This highlights significant remaining knowledge gaps in the complete genetic architecture, especially given that common susceptibility alleles are unlikely to contribute as strongly as well-known high-impact loci like factor V and ABO.^[18]

Variants

The genetic landscape of venous thromboembolism (VTE) involves a complex interplay of numerous genes and their variants, many of which influence the delicate balance of blood coagulation. These variants can affect the expression or function of key proteins in the clotting cascade, thereby modulating an individual’s susceptibility to thrombotic events.

The ABO gene, which determines an individual’s ABO blood group, is a well-established factor influencing VTE risk. Individuals with non-O blood types (A, B, or AB) generally exhibit higher plasma levels of von Willebrand Factor (vWF) and Factor VIII (FVIII), both crucial proteins in blood clotting, compared to those with O blood type.^[1] The ABO gene encodes glycosyltransferases that determine the presence of A and B antigens on cell surfaces, influencing the clearance and stability of vWF and FVIII, which directly impacts the coagulation cascade. Variants such as rs495828 , along with rs10901252 , rs2073826 , rs9411377 , rs579459 , and rs635634 within the ABO locus, likely contribute to the variability in vWF and FVIII levels, thereby modulating an individual’s susceptibility to thrombotic events.^[1] Another critical gene is F5, which encodes Factor V, a pivotal protein in the coagulation cascade. The variant rs6025 , commonly known as Factor V Leiden, is a prominent genetic risk factor for VTE.^[1]This specific mutation leads to a modified Factor V protein that is resistant to inactivation by activated protein C, resulting in a prolonged procoagulant state and an elevated risk of clot formation. Studies have consistently demonstrated a strong association betweenrs6025 and VTE.^[1] While rs2420372 and rs6427196 are also located within the F5 gene, their specific impact on Factor V activity and VTE risk is not as extensively characterized. Similarly, the F11 gene, which codes for Factor XI, another important coagulation factor, has been identified as a locus associated with VTE.^[1] Elevated levels of Factor XI are known to increase thrombotic risk, and variants such as rs3756011 , rs4253417 , and rs2036914 within F11 may influence Factor XI expression or activity, contributing to an individual’s predisposition to VTE.

Variants in other genes involved in coagulation pathways also contribute to VTE risk. The FGB gene encodes the beta chain of fibrinogen, a protein essential for blood clot formation, as it polymerizes to form the fibrin mesh that stabilizes a clot. While the specific variant rs2227402 is not extensively described, alterations in FGB can influence fibrinogen levels or the quality of the fibrin clot, thereby affecting susceptibility to VTE. The MCF2Lgene, or MCF2 Like, plays a role in cellular signaling as a guanine nucleotide exchange factor. While its direct involvement in VTE viars1046205 is not detailed, other variants in MCF2L have been broadly linked to coagulation factor levels.^[19] Furthermore, the HRG-AS1(Histidine Rich Glycoprotein Antisense 1) andKNG1 (Kininogen 1) genes, with the variant rs710446 , are also implicated. KNG1 produces kininogen, a precursor to bradykinin and a cofactor in the intrinsic coagulation pathway, affecting Factor XI activation. Variations in these genes could modulate the intricate balance of procoagulant and anticoagulant processes, influencing an individual’s risk for VTE.

Genetic variations in genes like NME7 and ATP1B1 are also under investigation for their potential links to VTE. NME7 (NME/NM23 Family Member 7) is part of a family of proteins involved in diverse cellular functions, including cell proliferation, differentiation, and signal transduction. While the precise mechanism by which rs1209731 and rs2040445 in NME7 influence VTE risk is complex, other variants in NME7 have been associated with VTE.^[1] These associations suggest that NME7 may play a role in processes related to vascular health or inflammation that indirectly affect coagulation. Similarly, ATP1B1(ATPase Na+/K+ Transporting Subunit Beta 1) encodes a component of the sodium-potassium pump, critical for maintaining cellular ion gradients and membrane potential. Although the specific variantsrs145163454 , rs75112989 , and rs2040445 within ATP1B1 are not fully characterized, other ATP1B1 variants have shown marginal associations with VTE risk.^[1] This suggests that variations in ATP1B1 might affect endothelial cell function or vascular integrity, potentially contributing to a prothrombotic state.

Key Variants

RS ID	Gene	Related Traits
rs10901252 rs2073826 rs9411377	ABO	hematocrit hemoglobin von Willebrand factor quality erythrocyte volume mean corpuscular hemoglobin concentration
rs1046205	MCF2L	factor VII venous thromboembolism circulating fibrinogen levels, factor VII Ischemic stroke, factor VII coronary artery disease, factor VII
rs6025 rs2420372 rs6427196	F5	venous thromboembolism inflammatory bowel disease peripheral arterial disease peripheral vascular disease pulmonary embolism
rs710446	HRG-AS1, KNG1	venous thromboembolism blood coagulation trait factor XI ESAM/SPINT2 protein level ratio in blood AGRP/NPY protein level ratio in blood
rs3756011 rs4253417 rs2036914	F11	protein blood protein amount venous thromboembolism Thromboembolism pulmonary embolism, Pulmonary Infarction
rs2227402	FGB	circulating fibrinogen levels, factor VII Ischemic stroke, circulating fibrinogen levels venous thromboembolism circulating fibrinogen levels, coronary artery disease
rs2040445	NME7, ATP1B1	venous thromboembolism endometriosis
rs1209731	NME7	venous thromboembolism lipoma blood coagulation disease
rs579459 rs635634 rs495828	ABO - Y_RNA	erythrocyte count total cholesterol low density lipoprotein cholesterol E-selectin amount coronary artery disease
rs145163454 rs75112989	ATP1B1	hemorrhoid venous thromboembolism thrombophilia blood coagulation disease deep vein thrombosis

Defining Venous Thromboembolism and its Core Components

Venous thromboembolism (VTE) is a pathological condition characterized by the formation of a blood clot, known as a thrombus, within a vein. This umbrella term primarily encompasses two major clinical manifestations: deep vein thrombosis (DVT) and pulmonary embolism (PE).^[20]Deep vein thrombosis typically involves the formation of clots in the deep veins, most commonly in the legs, leading to symptoms such as pain and swelling. Pulmonary embolism occurs when a portion of a DVT dislodges, travels through the bloodstream, and lodges in the pulmonary arteries, obstructing blood flow to the lungs and potentially causing severe respiratory and cardiovascular compromise.^[21]VTE is a significant health concern, with epidemiological studies highlighting its association with various risk factors including advanced age, female sex, higher Body Mass Index (BMI), smoking, diabetes, and a history of cancer.^[16]

Classification and Clinical Manifestations

The classification of VTE is primarily based on its anatomical location and clinical presentation, distinguishing between DVT and PE. While these are often considered distinct entities, PE is frequently a direct complication of DVT, arising when a clot from the deep venous system embolizes to the lungs.^[22]Although venous and arterial thrombosis represent different aspects of thrombotic disease, research continues to explore potential overlaps and shared genetic predispositions between these conditions.^[23]Further classification can involve the identification of predisposing factors, with studies examining the joint effects of various anthropometric measures, such as obesity and body height, on the overall risk of VTE.^[24]

Diagnostic Criteria and Associated Terminology in Research

In research settings, the operational definition of VTE cases often relies on robust diagnostic criteria derived from electronic health records (EHR) or self-reported events, meticulously validated to ensure accuracy.^[16] Controls are typically defined as individuals who do not meet the VTE case definition and have a documented history of multiple healthcare encounters, suggesting a lack of undiagnosed VTE. approaches for risk factors are critical, with BMI, for instance, often adjusted for confounding variables like age and sex, and then utilized in genetic risk scores for Mendelian randomization analyses to infer causal relationships.^[16] Key terminology in VTE pathogenesis and risk assessment includes concepts related to genetic variation within anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways, as well as plasma levels of factors like von Willebrand factor and tissue factor pathway inhibitor, which are implicated in thrombotic risk.^[25]

Clinical Manifestations and Phenotypes

Venous thromboembolism (VTE) encompasses two primary clinical manifestations: deep vein thrombosis (DVT) and pulmonary embolism (PE), which can occur independently or concurrently.^[26] DVT typically involves the formation of a blood clot in a deep vein, most commonly in the leg or arm.^[26] PE, a potentially life-threatening condition, occurs when a part of a DVT dislodges and travels to the lungs. The presentation of VTE can vary significantly, ranging from asymptomatic cases to severe, acute events that necessitate immediate medical intervention.

VTE can be categorized as either provoked or unprovoked, reflecting different presentation patterns and underlying risk factors. Provoked VTE is associated with identifiable external factors such as recent surgery, trauma, immobilization, hormone use, or the presence of cancer.^[14] In contrast, unprovoked VTE occurs without such clear precipitating events. This distinction is crucial for diagnostic and prognostic considerations, as individuals with unprovoked VTE face a higher risk of recurrent events.

Diagnostic Assessment and Biomarkers

The diagnosis of VTE often relies on objective confirmation methods, although specific imaging techniques like ultrasound for DVT or CT pulmonary angiography for PE are not detailed in research.^[26]Beyond clinical evaluation, a range of quantitative biomarkers are investigated for their association with VTE pathophysiology and hemostatic traits. These include D-dimers, which are widely used to rule out VTE, and measures of endogenous thrombin generation.^[14] Further diagnostic insights can be gained from assessing plasma antigen or activity levels of various coagulation factors, such as fibrinogen, factors II, VII, VIII, IX, X, and XII.^[14]Other relevant biomarkers include von Willebrand factor, antithrombin, protein C, protein S (both total and free), and protein Z, alongside routine hematological parameters like activated partial thromboplastin time, hemoglobin, and white blood cell and platelet counts.^[14] These objective measures contribute to a comprehensive diagnostic picture and help in understanding the complex biological pathways involved in thrombus formation.

Variability, Risk Factors, and Recurrence

The clinical presentation and incidence of VTE exhibit considerable variability across individuals, influenced by demographic factors and co-existing conditions. For instance, the average age of VTE cases in studies has been reported around 59.5 ± 7.2 years, with a notable proportion of male individuals (43.3%).^[27]Several clinical phenotypes and comorbidities are strongly correlated with VTE, including prevalent cancer, smoking history, hypertension, diabetes mellitus, hyperlipidemia, and higher body mass index (BMI).^[27]Obesity, in particular, has been implicated as a causal risk factor, highlighting the impact of metabolic health on VTE susceptibility.^[27]The diagnostic significance of these factors extends to prognostic indicators, particularly concerning the risk of recurrence. The overall recurrence risk of venous thrombosis is approximately 6% per year, with about 25% of patients developing post-thrombotic disease within five years following an initial event.^[6] A significant proportion (around 20%) of individuals experiencing unprovoked VTE will suffer a recurrent event, even after standard anticoagulant prophylaxis.^[14] Understanding the phenotypic diversity and genetic predispositions, such as those associated with TSPAN15 and SLC44A2.^[14] is essential for refining prevention strategies and identifying individuals at higher risk of adverse outcomes.

Causes of Venous Thromboembolism

Venous thromboembolism (VTE) is a complex disease resulting from an intricate interplay of genetic predispositions, environmental exposures, and other clinical factors. It is recognized as a multicausal condition, where various elements contribute to an individual’s overall risk of developing deep vein thrombosis (DVT) or pulmonary embolism (PE).^[28]

Genetic Predisposition and Heritability

VTE is significantly influenced by inherited genetic factors, with its narrow-sense heritability estimated to be approximately 30%.^[29] Familial segregation of VTE has been consistently observed, underscoring a strong inherited component to its etiology.^[30] Genome-wide association studies (GWAS) have identified numerous common genetic variants contributing to VTE risk, including specific loci on chromosomes 1q24.2 and 9q.^[1] Further research has expanded this understanding, pinpointing additional susceptibility loci such as TSPAN15, SLC44A2.^[14] and ZFPM2.^[27] highlighting the polygenic nature of VTE.

Beyond these common variants, specific inherited mutations and polymorphisms in genes central to coagulation and fibrinolysis pathways play a critical role. Well-established risk factors include variants in the FV (Factor V Leiden) and ABO blood group loci, which are significant contributors to VTE risk.^[18] Genetic variations within the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways are recognized as important risk factors.^[25] Polymorphisms in the fibrinogen gamma gene (FGG), such as the 10034C>T variant, are associated with VTE, potentially by reducing plasma fibrinogen gamma’ levels.^[31] Similarly, the KNG1 Ile581Thr variant has been linked to increased susceptibility to VTE.^[32] and genetic variations influencing von Willebrand factor levels are also associated with VTE risk.^[8] The cumulative effect of multiple genetic variants and potential gene-gene interactions further complicates the genetic landscape of VTE.^[17]

Environmental and Lifestyle Influences

Environmental and lifestyle factors are crucial determinants in the development of VTE.^[29]These external influences encompass a range of exposures, including dietary habits, physical activity levels, and socioeconomic conditions, all of which can modify an individual’s risk profile.^[21]A significant environmental risk factor identified is obesity, which has been established as a causal factor for VTE through Mendelian randomization studies.^[27] Elevated anthropometric measures and increased body fat are consistently associated with a higher incidence of VTE.^[33] Additionally, certain physical characteristics, such as body height, have been identified as independent risk factors for VTE.^[34] While the exact mechanisms by which some environmental factors contribute to VTE are still being elucidated, they are understood to impact hemostatic balance, endothelial function, and blood flow, collectively increasing the likelihood of thrombus formation.

Interplay of Genes and Environment

Venous thromboembolism is widely characterized as a multicausal disease, arising from complex interactions between an individual’s genetic makeup and their environmental exposures.^[28]Genetic predispositions, such as carrying specific risk variants in coagulation pathway genes, do not independently dictate disease onset but rather modulate an individual’s susceptibility to environmental triggers.^[35]For example, while a genetic variant might confer a baseline increased risk, the actual manifestation of VTE can be precipitated or exacerbated by lifestyle factors like obesity or prolonged immobility.

This gene-environment interaction highlights how genetic susceptibility can be potentiated or mitigated by external factors, leading to a varied risk profile among individuals. Understanding these intricate interactions is essential for comprehensively assessing VTE risk and developing targeted preventive strategies.

Other Clinical and Age-Related Factors

Beyond genetic and environmental influences, several other clinical and demographic factors contribute significantly to VTE risk. Age is a prominent factor, with studies revealing age- and gender-specific familial risks for VTE, indicating that the risk profile evolves throughout an individual’s lifespan.^[36] As individuals age, changes in vascular health, coagulation system activity, and overall physiological resilience can collectively increase susceptibility to thrombotic events.

Furthermore, the presence of certain comorbidities can independently or synergistically elevate VTE risk. For instance, research has investigated whether conditions like diabetes mellitus act as independent risk factors for VTE.^[37] While the specific mechanisms linking all comorbidities to VTE are diverse, they often involve systemic inflammation, endothelial dysfunction, or altered blood viscosity, all contributing to a prothrombotic state.

Biological Background of Venous Thromboembolism

Venous thromboembolism (VTE), encompassing deep venous thrombosis (DVT) and pulmonary embolism (PE), represents a significant cardiovascular condition associated with substantial mortality.^[38]It is considered the third most common life-threatening cardiovascular condition, trailing only coronary heart disease and stroke.^[38] VTE is characterized by the formation of blood clots, typically in the deep veins of the legs (DVT), which can then dislodge and travel to the lungs (PE), obstructing blood flow.^[38] The etiology of VTE is complex, involving a delicate balance of molecular, cellular, and genetic factors that govern blood coagulation and its regulation.

Pathophysiology and Systemic Consequences: Virchow’s Triad

The foundational understanding of VTE pathophysiology is encapsulated in Virchow’s triad, which identifies three primary contributing factors: endothelial injury or activation, reduced blood flow (stasis), and hypercoagulability of the blood.^{[9], [14], [39]}Endothelial injury, often resulting from trauma, surgery, or inflammation, exposes subendothelial collagen and tissue factor, initiating the coagulation cascade. Reduced blood flow, common in prolonged immobility, surgery, or conditions like obesity, prevents the dilution of activated clotting factors and hinders the delivery of natural anticoagulants to the site of potential clot formation.^{[14], [22], [33]} Hypercoagulability, whether inherited or acquired, refers to an increased propensity for blood to clot, often due to an imbalance between procoagulant and anticoagulant factors.^[14]These factors can act synergistically, leading to thrombus formation in the venous system, with systemic consequences ranging from localized pain and swelling in DVT to life-threatening respiratory and circulatory compromise in PE.^[38]

Molecular and Cellular Pathways of Coagulation

The formation and dissolution of blood clots involve intricate molecular and cellular pathways, primarily the coagulation cascade and fibrinolysis. The coagulation cascade is a series of enzymatic reactions involving critical proteins known as clotting factors, enzymes, and cofactors, ultimately leading to the conversion of soluble fibrinogen into insoluble fibrin, which forms the structural meshwork of a clot.^{[25], [38]}Key biomolecules include prothrombin, which is cleaved to thrombin, and Factor V, which, as activated Factor Va, significantly amplifies thrombin generation.^{[7], [40]}Counteracting this procoagulant activity are natural anticoagulant proteins such as antithrombin, protein C, and protein S, which inhibit specific activated clotting factors, thereby regulating clot formation.^[14] Fibrinolysis, on the other hand, is the process of clot breakdown, primarily mediated by plasmin, an enzyme that degrades fibrin, ensuring the timely removal of thrombi and maintaining vascular patency.^[38] Disruptions in the balance of these regulatory networks, whether due to genetic variants or acquired conditions, can lead to a hypercoagulable state favoring VTE.

Genetic Mechanisms of VTE Susceptibility

Venous thromboembolism has a strong genetic basis, with heritability estimates ranging from 50% to 60%, indicating a substantial genetic predisposition.^{[1], [14], [35], [38], [41]}Several well-established genetic risk factors contribute to inherited hypercoagulable states. These include heterozygous deficiencies in natural coagulation inhibitors like antithrombin, protein C, and protein S, which are relatively rare but significantly increase VTE risk.^[14] More prevalent genetic variants include the Factor V (F5) Leiden mutation, which results in activated protein C resistance, and the prothrombin (F2) G20210A variant, leading to elevated plasma prothrombin levels.^{[7], [14], [40]} Additionally, a common genetic variation in the fibrinogen gamma prime (FGG) gene, rs2066865 , and non-O blood group are also significant risk factors, influencing fibrinogen structure and plasma levels of various clotting factors respectively.^{[1], [14], [31]} These genetic mechanisms highlight how specific gene functions and expression patterns directly impact the delicate balance of hemostasis.

Emerging Genetic Loci and Modulating Factors

Beyond the classical genetic risk factors, genome-wide association studies (GWAS) have identified additional susceptibility loci for VTE, expanding the understanding of its complex genetic architecture. Loci such as TSPAN15 and SLC44A2 have been implicated, alongside variants on chromosomes 1q24.2 and 9q.^{[1], [14], [38]} The F11 locus, associated with Factor XI levels, also contributes to VTE risk.^[42] Polymorphisms in genes like C4BPB/C4BPA and the KNG1 Ile581Thr variant have been identified as new susceptibility loci, further diversifying the genetic landscape of VTE.^{[32], [43]} Moreover, genetic variations influencing plasma von Willebrand factor (vWF) and Factor VIII (F8) levels are recognized risk factors, as elevated levels of these key biomolecules can promote thrombosis.^{[8], [44], [45], [46]} Recent research has also identified the ZFPM2locus and implicated obesity as a causal risk factor, underscoring the interplay between genetic predisposition, metabolic processes, and environmental influences in VTE development.^{[22], [27]}

Core Coagulation and Fibrinolysis Dynamics

Venous thromboembolism (VTE) fundamentally arises from dysregulation within the intricate balance of procoagulant and anticoagulant pathways, alongside the fibrinolytic system that controls clot breakdown. Key components include Factor V (FV), where a common mutation leads to resistance to activated protein C (APC), significantly increasing VTE risk by impairing a critical anticoagulant feedback loop.^[7]Similarly, variations in the prothrombin gene’s 3′-untranslated region are associated with elevated plasma prothrombin levels, leading to increased thrombin generation and enhanced clot formation.^[40] The ABO blood group also contributes to VTE risk, further illustrating genetic influences on baseline coagulation factor levels.^[18]The coagulation cascade is further modulated by other factors such as Factor VII (FVII), Factor VIII (FVIII), and Factor XI (FXI), with genetic variations impacting their circulating levels and activity.^[8] High FVIII antigen levels, for instance, are linked to an increased risk of venous thrombosis.^[45] Conversely, the natural anticoagulant Tissue Factor Pathway Inhibitor (TFPI) plays a crucial regulatory role, with low plasma levels increasing the risk of both initial and recurrent VTE events, including cerebral venous thrombosis, by reducing the inhibition of the extrinsic coagulation pathway.^[47] The fibrinolytic system, responsible for dissolving clots, involves components like Plasminogen Activator Inhibitor-1 (PAI-1) and tissue Plasminogen Activator (tPA); PAI-1 overexpression can promote thrombosis, while an ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis, highlighting a critical balance in clot resolution.^[48]

Inflammatory and Endothelial Interactions

The endothelium, the inner lining of blood vessels, acts as a dynamic interface, and its dysfunction along with inflammatory processes are integral to VTE pathogenesis. Inflammatory markers and coagulation factors are intertwined, with studies showing their combined relevance in VTE.^[49]For example, Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been identified as a potential therapeutic target for post-thrombotic syndrome, indicating its role in the inflammatory response following thrombosis.^[50]Monocytes, a type of immune cell, contribute to the resolution of deep vein thrombosis throughCXCR2-mediated activity, underscoring the cellular immune response in thrombus remodeling.^[51] Furthermore, the tissue kallikrein-kinin system, known for its role in vascular remodeling and inflammation, can influence deep venous thrombosis, with genetic variants in genes like BDKRB2 and KNG1 affecting its components.^[52] Endothelial proteins such as STXBP5 and STX2 are also implicated in regulating circulating levels of tPA, directly linking endothelial health to fibrinolytic capacity.^[53]

Genetic Regulatory Mechanisms and Risk Factors

Genetic predisposition significantly influences an individual’s susceptibility to VTE, with numerous loci identified through genome-wide association studies (GWAS). These studies have revealed common susceptibility alleles, such as those in TSPAN15 and SLC44A2, and risk variants on chromosomes 1q24.2 and 9q.^[14] More recent analyses have further expanded this understanding by identifying the ZFPM2locus and 16 novel susceptibility loci for VTE, demonstrating the polygenic nature of the disease.^[16] Beyond single gene effects, gene-gene interactions play a role in modulating VTE risk, with ongoing research aiming to decipher these complex network interactions.^[17]The genetic architecture of VTE involves variations within not only anticoagulant and procoagulant pathways but also fibrinolytic and innate immunity pathways, highlighting the systems-level integration of these regulatory mechanisms in disease etiology.^[1]

Metabolic and Systemic Modulators of Thrombosis

Systemic factors, including metabolic state and anthropometric traits, are critical modulators of VTE risk, often integrating with genetic predispositions. Obesity, for instance, is strongly implicated as a causal risk factor for VTE, with studies demonstrating a clear association between increased body fat and the incidence of the condition.^[24]While the precise metabolic pathways linking obesity to VTE are complex, they likely involve alterations in inflammatory profiles, endothelial function, and coagulation factor levels. Height also interacts with obesity to influence VTE risk, reflecting a broader systems-level integration of physical characteristics and metabolic health in disease susceptibility.^[24]The recognition of genetic overlap between VTE and arterial vascular disease underscores a broader pathological continuum in vascular health, suggesting shared underlying mechanisms and pathway crosstalk at a systemic level.^[23] This integrative perspective reinforces Virchow’s triad—stasis, endothelial injury, and hypercoagulability—as a foundational framework for understanding the multifaceted etiology of VTE.^[9]

Genetic Modulators of Coagulation and Thrombotic Risk

Genetic variations significantly influence an individual’s susceptibility to venous thromboembolism (VTE) by modulating key components of the coagulation cascade. A prominent example is the Factor V Leiden mutation,FV:R506Q (rs6025 ), in the F5gene, which confers resistance to activated protein C, a natural anticoagulant. This leads to a procoagulant state, substantially increasing the risk of VTE.^[7] Similarly, ABO blood group alleles are strongly associated with VTE risk, with non-O blood types generally linked to higher levels of von Willebrand factor and factor VIII, thereby influencing the overall thrombotic potential.^[18] These genetic predispositions fundamentally alter the biological “target” environment for antithrombotic drugs, making the coagulation system inherently more prone to clot formation.

Beyond these well-established factors, other genetic variants contribute to the intricate balance of hemostasis. Polymorphisms in genes such as F12, KNG1, and HRG have been associated with variations in activated partial thromboplastin time (aPTT), a measure of intrinsic and common coagulation pathways.^[54] Additionally, a polymorphism (rs1799987 ) in the low-density lipoprotein receptor-related protein 1 (LRP1) gene, specifically 663 C > T, has been shown to affect clotting factor VIII activity, further impacting VTE risk.^[55] These variations highlight how genetic differences in target proteins and signaling pathways can predispose individuals to VTE, setting the stage for potential differential responses to antithrombotic interventions.

Pharmacodynamic Implications for Antithrombotic Therapy

The presence of VTE susceptibility genes, such as the FV:R506Q mutation, creates an altered baseline hemostatic profile that can have significant pharmacodynamic implications for antithrombotic therapies. Individuals with such prothrombotic genotypes possess an inherent imbalance favoring clot formation, which may necessitate different therapeutic approaches to achieve adequate anticoagulation and prevent recurrent events.^[7] While specific drug-gene interactions detailing dose adjustments based on these susceptibility variants are not explicitly defined in some contexts, the underlying genetic predisposition suggests that standard antithrombotic regimens might exhibit reduced efficacy or require more vigilant monitoring in genetically high-risk individuals. This altered pharmacodynamic environment means that the therapeutic response to anticoagulants could be diminished, potentially contributing to breakthrough events or a higher risk of recurrence.

The cumulative effect of multiple genetic variants on coagulation pathways can further complicate the pharmacodynamic landscape. For instance, the combined influence of F5 Leiden and ABO blood group on VTE risk underscores a multifactorial genetic contribution to the overall prothrombotic tendency.^[18] Understanding these complex interactions, even without direct drug metabolism data, is crucial for anticipating the effectiveness of antithrombotic agents. A patient with a strong genetic predisposition to VTE may require more intensive or prolonged anticoagulation, or a different choice of agent, to overcome their inherent prothrombotic state and achieve optimal therapeutic outcomes, thereby impacting personalized prescribing strategies and drug efficacy.

Clinical Utility in Risk Stratification and Personalized Management

The identification of genetic variants associated with VTE susceptibility holds considerable promise for enhancing personalized clinical management, particularly in contexts of elevated risk such as postoperative recovery. Studies have shown that genetic variations within anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways act as risk factors for VTE, allowing for improved risk stratification.^[1] For example, assessing an individual’s genotype for FV:R506Q or ABO blood group can help identify patients at a significantly higher baseline risk of VTE, informing decisions regarding the intensity and duration of prophylactic measures following surgery.^[56] This personalized approach to risk assessment can guide drug selection, not necessarily by altering drug metabolism, but by determining the necessity of antithrombotic prophylaxis or the choice of a more potent agent for high-risk individuals.

Ongoing genome-wide association studies (GWAS) continue to uncover novel susceptibility loci for VTE, including variants in genes like TSPAN15, SLC44A2, and ZFPM2.^[14]While these discoveries further elucidate the genetic architecture of VTE, they also highlight the complexity, as known polymorphisms currently explain only a fraction of the disease’s genetic variance.^[17] Integrating this growing body of genetic information into clinical practice allows for more refined patient phenotyping and personalized prescribing by identifying individuals who may benefit most from targeted VTE prevention strategies, optimizing patient outcomes by aligning treatment intensity with individual genetic risk profiles.

Frequently Asked Questions About Venous Thromboembolism

These questions address the most important and specific aspects of venous thromboembolism based on current genetic research.

---

1. My parent had a blood clot. Does that mean I’m more likely to get one?

Yes, if a parent had a blood clot, your risk is significantly higher. Venous thromboembolism (VTE) is highly heritable, with genetic factors accounting for 35% to 62% of the risk. This means you may have inherited genetic predispositions that make you more susceptible to clot formation.

2. I have a desk job. Does sitting all day increase my risk for blood clots?

Yes, prolonged sitting can increase your risk for blood clots. Lack of movement leads to blood stasis, which is one of the primary factors in Virchow’s triad, a foundational understanding of VTE pathophysiology. While genetics influence your inherent susceptibility, environmental factors like immobility are crucial contributors.

3. Why do some people get blood clots easily, even when they seem healthy?

It’s often due to underlying genetic predispositions that affect blood coagulation. Some individuals carry specific genetic variants, such as Factor V Leiden or the prothrombin G20210A variant, which make their blood more prone to clotting or less effective at breaking clots down. These genetic differences can increase their risk even without obvious external triggers.

4. Can a DNA test tell me if I’m at high risk for a blood clot?

Yes, a DNA test can identify some of the specific genetic variants known to increase VTE risk, like Factor V Leiden and the prothrombin G20210A mutation. However, these known genetic polymorphisms currently explain only about 5% of the total genetic variance. So, while helpful, a test might not capture your full genetic susceptibility.

5. If blood clots run in my family, can I still prevent them with lifestyle changes?

Yes, absolutely. While you can’t change your genes, lifestyle choices play a significant role. Even with a genetic predisposition, staying active, avoiding prolonged immobility, and managing other risk factors can help reduce your chances of developing a clot. Understanding your genetic risk can also help in developing personalized prevention strategies.

6. Is it true that older people are just more likely to get blood clots?

Yes, that’s true. The incidence of venous thromboembolism increases exponentially with age for both men and women. While the specific genetic mechanisms for this age-related increase are complex, age is a well-established and significant risk factor that interacts with any inherited genetic susceptibility.

7. If I get injured, does that raise my chances of developing a blood clot?

Yes, injuries can definitely raise your chances of developing a blood clot. Physical trauma or damage to the lining of blood vessels (endothelial injury) is a key component of Virchow’s triad, which contributes to clot formation. This injury, especially when combined with genetic predispositions, can significantly increase your risk.

8. My sibling and I are very different; why might one of us get clots and not the other?

Even among siblings, there can be differences in inherited genetic variants and environmental exposures. While VTE is highly heritable, each person’s unique combination of genetic predispositions and life experiences interacts to determine their overall risk. One sibling might have inherited more risk-associated variants or encountered more environmental triggers.

9. Does my family’s background make me more prone to blood clots?

Yes, your family’s genetic background plays a significant role in your risk for blood clots. Venous thromboembolism is highly heritable, meaning genetic predispositions are passed down through generations. Certain genetic variants, such as Factor V Leiden, are more prevalent in specific populations, which could influence your inherited risk.

10. Is it possible to have a genetic risk for clots but never actually get one?

Yes, it’s absolutely possible. Having a genetic predisposition means you have an increasedlikelihood, not a certainty. Blood clot formation is a complex interplay of many genetic and environmental factors. You might carry risk variants, but if you maintain a healthy lifestyle and avoid significant environmental triggers, you may never develop a clot.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Heit JA, Armasu SM, Asmann YW, Cunningham JM, Matsumoto ME, Petterson TM, De Andrade M. “A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q.”J Thromb Haemost. 2012; 10(8):1521-1531.

[2] Anderson, FA Jr. et al. “A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.”Arch Intern Med, vol. 151, no. 5, 1991, pp. 933–8.

[3] Goldhaber, SZ. “Epidemiology of pulmonary embolism and deep vein thrombosis.”Haemostasis and Thrombosis, 3rd ed., edited by Bloom, AL et al., Churchill Livingstone, 1994, pp. 1327-1333.

[4] Deitelzweig, SB et al. “Prevalence of clinical venous thromboembolism in the USA: current trends and future projections.”Am J Hematol, vol. 86, no. 2, 2011, pp. 217–20.

[5] Tagalakis, V et al. “Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort.”Am J Med, vol. 126, no. 9, 2013, pp. 832.e13–21.

[6] Germain, M et al. “Genetics of venous thrombosis: insights from a new genome wide association study.” PLoS One, vol. 6, no. 10, 2011, p. e25581.

[7] Bertina, R.M. et al. “Mutation in blood coagulation factor V associated with resistance to activated protein C.”Nature, vol. 369, 1994, pp. 64–67.

[8] Smith NL, Rice KM, Bovill EG, Cushman M, Bis JC, McKnight B, et al. “Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis.” Blood. 2011; 117(22):6007-6011.

[9] Kyrle, P.A. and S. Eichinger. “Is Virchow’s triad complete?” Blood, vol. 114, 2009, pp. 1138–1139.

[10] Beckman, MG et al. “Venous thromboembolism: a public health concern.”Am J Prev Med, vol. 38, no. 4 Suppl, 2010, pp. S495–501.

[11] Coombes, R. “Venous thromboembolism caused 25,000 deaths a year, say MPs.”BMJ, vol. 330, no. 7491, 2005, p. 559.

[12] MacDougall, DA et al. “Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.”Am J Health Syst Pharm, vol. 63, no. 10 Suppl 5, 2006, pp. S5–15.

[13] Grosse, SD et al. “The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.”Thromb Res, vol. 137, 2016, pp. 3–10.

[14] Germain M, Chasman DI, de Haan H, Tang W, Lindstrom S, Weng LC, de Andrade M, de Visser MC, Wiggins KL, Suchon P, et al. “Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.”Am J Hum Genet. 2015; 96(4):532-542.

[15] Hinds, D. A., et al. “Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.” Hum Mol Genet, vol. 25, no. 9, 2016, 1867–74.

[16] Klarin, D et al. “Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.”Circ Cardiovasc Genet, vol. 11, no. 3, 2018, p. e001716.

[17] Greliche N, Saut N, Perret C, Oudot-Mellakh T, Alessi MC, Morange PE, et al. “A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis.” BMC Med Genet. 2013; 14:38.

[18] Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, et al. “Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.” Blood. 2009; 113(22):5298-5303.

[19] Williams, Francesca M., et al. “Ischemic stroke is associated with the ABO locus: the EuroCLOT study.”Annals of Neurology, vol. 73, no. 3, 2013, pp. 329-338.

[20] Heit, J.A., et al. “The epidemiology of venous thromboembolism.”J Thromb Thrombolysis, vol. 41, 2016, pp. 3–14.

[21] Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJI. “Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.”Arch Intern Med. 2000; 160(6):809-815.

[22] Klovaite J, Benn M, Nordestgaard BG. “Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study.”J Intern Med. 2015; 277(5):573-584.

[23] Prandoni, P. “Venous and arterial thrombosis: two aspects of the same disease?”Eur. J. Intern. Med., vol. 20, 2009, pp. 660–661.

[24] Borch, K.H., et al. “Joint effects of obesity and body height on the risk of venous thromboembolism: the Tromso Study.”Arterioscler. Thromb. Vasc. Biol., vol. 31, 2011, pp. 1439–1444.

[25] Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, De Andrade M. “Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.”J Thromb Haemost. 2011; 9(6):1133-1142.

[26] Heit, J. A., et al. “Identification of unique venous thromboembolism-susceptibility variants in African-Americans.”Thromb Haemost, vol. 117, no. 5, 2017, 946–55.

[27] Klarin D, Lynch J, Ng K, Logsdon BA, Pulit SL, Damrauer SM, et al. “Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.”Circ Cardiovasc Genet. 2017; 10(2):e001512.

[28] Rosendaal FR. “Venous thrombosis: a multicausal disease.”Lancet. 1999; 353(9160):1167-1173.

[29] Klarin D, Richter LM, Saccone SF, Gilland AT, Levin MG, Natarajan P, et al. “Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.”Nat Genet. 2019; 51(12):1733-1742.

[30] Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, De Andrade M. “Familial segregation of venous thromboembolism.”J Thromb Haemost. 2004; 2(5):731-736.

[31] Grunbacher G, Weger W, Marx-Neuhold E, Pilger E, Koppel H, Wascher T, Marz W, Renner W. “The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.” Thromb Res. 2007; 121(1):33-36.

[32] Morange PE, Oudot-Mellakh T, Cohen W, Germain M, Saut N, et al. “KNG1 Ile581Thr and susceptibility to venous thrombosis.” Blood. 2011; 117(13):3692-3694.

[33] Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjonneland A, Overvad K. “Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study.”Circulation. 2009; 120(19):1850-1857.

[34] Braekkan SK, Borch KH, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. “Body height and risk of venous thromboembolism: the Tromso Study.”Am J Epidemiol. 2010; 171(10):1109-1115.

[35] Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, et al. “Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.” Am J Hum Genet. 2000; 67(6):1452-1459.

[36] Zoller B, Li X, Sundquist J, Sundquist K. “Age- and gender-specific familial risks for venous thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden.”Circulation. 2011; 124(9):1012-1020.

[37] Heit JA, Leibson CL, Ashrani AA, Petterson TM, Bailey KR, Melton LJ III. “Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study.”Arterioscler Thromb Vasc Biol. 2009; 29(9):1399-1405.

[38] Tang W, Chasman DI, de Andrade M, de Visser MC, Wiggins KL, Suchon P, et al. “A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.”Genet Epidemiol. 2012; 36(8):792-801.

[39] Bagot, C.N. and R. Arya. “Virchow and his triad: a question of attribution.” Br. J. Haematol., vol. 143, no. 2, 2008, pp. 180–190.

[40] Poort, S.R. et al. “A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.” Blood, vol. 88, 1996, pp. 3698–3703.

[41] Larsen, T.B. et al. “Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins.”Epidemiology, vol. 14, 2003, pp. 328–332.

[42] Li, Y. et al. “Genetic variants associated with deep vein thrombosis: the F11 locus.”J Thromb Haemost., vol. 7, 2009, pp. 1802–1808.

[43] Buil, A. et al. “C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies.”Blood, vol. 115, 2010, pp. 4644–4650.

[44] Williams, S.R. et al. “Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke.”Stroke, vol. 48, no. 6, 2017, pp. 1475–1481.

[45] Kamphuisen, P.W. et al. “High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene.” Br J Haematol., vol. 115, 2001, pp. 156–158.

[46] Koster, T. et al. “Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.”Lancet, vol. 345, 1995, pp. 152–155.

[47] Javanmard, S.H., et al. “Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis.” Adv. Biomed. Res., vol. 4, 2015, p. 6.

[48] Eitzman, D.T., et al. “Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.” Blood, vol. 95, 2000, pp. 577–580.

[49] Tsai, A.W. et al. “Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).”Am J Med., vol. 113, 2002, pp. 636–642.

[50] Wojcik, B.M., et al. “Interleukin-6: a potential target for post-thrombotic syndrome.” Ann Vasc Surg, vol. 25, 2011, pp. 229–239.

[51] Henke, P.K., et al. “Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model.”Arterioscler Thromb Vasc Biol, vol. 24, 2004, pp. 1130–1137.

[52] Madeddu, P., et al. “Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling.”Nat Rev Nephrol, vol. 3, 2007, pp. 208–221.

[53] Huang, J., et al. “Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation.” Blood, vol. 120, 2012, pp. 4873–4881.

[54] Houlihan, L.M., et al. “Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time.” Am J Hum Genet, vol. 86, no. 4, 2010, pp. 605-611.

[55] Vormittag, R., et al. “Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism.”J Thromb Haemost, vol. 5, 2007, pp. 497–502.

[56] Christensen, M. A., et al. “An assessment of the effect of the genotype on postoperative venous thromboembolism risk in 140,831 surgical patients.”Ann Med Surg (Lond), vol. 71, 2021, p. 102938.